Australia Leads the Way in Psychedelic Therapy for Mental Health

Australia has become the first country to classify psychedelics as medicines at a national level, with the approval of psilocybin for treatment-resistant depression and MDMA for post-traumatic stress disorder (PTSD). While hailed as a landmark moment by experts and patients, major health organizations have urged caution, calling for larger-scale studies and better research into psychedelic treatments due to unknown risks, potential long-term side effects, and limited benefits. The cost of treatment is expected to be high, making it unaffordable for most patients without government subsidies.